Lercanidipina Atral

Lercanidipine Hydrochloride, the active ingredient in Lercanidipina Atral, is a calcium channel blocker presented as an oral dosage form for oral use. It is employed to lower elevated blood pressure in adult patients with hypertension. The medication works by relaxing arterial smooth muscle, decreasing peripheral vascular resistance, and conforms to European Union quality standards and GMP manufacturing.

GNH USA supplies Lercanidipina Atral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery to diverse healthcare settings across multiple continents.

Lercanidipine is a calcium channel blocker used to manage hypertension, the primary disease pathway it influences.

- Essential hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension. - Isolated systolic hypertension: reduces elevated systolic pressure, particularly in older adults. - Secondary hypertension (as adjunct therapy): contributes to blood pressure control when combined with other antihypertensives.

Lercanidipine may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the lower limbs due to fluid accumulation. - Dizziness: sensation of light‑headedness, especially upon standing.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue or airway requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure that may cause fainting. - Myocardial infarction: rare occurrence of heart attack, particularly in patients with pre‑existing coronary disease.

Before initiating therapy with lercanidipine, several safety considerations should be reviewed. - Renal impairment: monitor kidney function and adjust therapy as needed. - Hepatic impairment: use with caution; dose adjustments may be required. - Concomitant CYP3A4 inhibitors: avoid or reduce dose due to increased plasma concentrations. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Elderly patients: start at low dose and monitor for orthostatic hypotension. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Lercanidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may cause excessive hypotension. - Grapefruit juice: increases drug exposure and risk of adverse effects. - Combined use with other antihypertensives (e.g., ACE inhibitors, diuretics): may lead to additive blood pressure lowering.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Beta‑blockers: may mask tachycardia signs of hypotension. - Lithium: may increase serum lithium levels, requiring monitoring.